

## Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome)

Reincke, Martin; Albani, Adriana; Assie, Guillaume; Bancos, Irina; Brue, Thierry; Buchfelder, Michael; Chabre, Olivier; Ceccato, Filippo; Daniele, Andrea; Detomas, Mario; Di Dalmazi, Guido; Elenkova, Atanaska; Findling, James; Grossman, Ashley; Gomez-Sanchez, Celso; Heaney, Anthony; Honegger, Jurgen; Karavitaki, Niki; Lacroix, André; Laws, Edward

DOI:

[10.1530/EJE-20-1088](https://doi.org/10.1530/EJE-20-1088)

License:

None: All rights reserved

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Reincke, M, Albani, A, Assie, G, Bancos, I, Brue, T, Buchfelder, M, Chabre, O, Ceccato, F, Daniele, A, Detomas, M, Di Dalmazi, G, Elenkova, A, Findling, J, Grossman, A, Gomez-Sanchez, C, Heaney, A, Honegger, J, Karavitaki, N, Lacroix, A, Laws, E, Losa, M, Murakami, M, Newell-Price, J, Pecori, F, Perez-Rivas, LG, Pivonello, R, Rainey, W, Sbiera, S, Schopohl, J, Stratakis, CA, Theodoropoulou, M, Van Rossum, E, Valassi, E, Zacharieva, S, Rubinstein, G & Ritzel, K 2021, 'Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations', *European Journal of Endocrinology*, vol. 184, no. 3, pp. P1–P16. <https://doi.org/10.1530/EJE-20-1088>

[Link to publication on Research at Birmingham portal](#)

### **Publisher Rights Statement:**

Disclaimer: this is not the definitive Version of Record of this article. This manuscript has been accepted for publication in European Journal of Endocrinology, but the version presented here has not yet been copy-edited, formatted or proofed. Consequently, Bioscientifica accepts no responsibility for any errors or omissions it may contain.

### **General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### **Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

## Authors:

Martin Reincke<sup>1\*§</sup>, Adriana Albani<sup>1\*</sup>, Guillaume Assie<sup>2</sup>, Irina Bancos<sup>3</sup>, Thierry Brue<sup>4</sup>, Michael Buchfelder<sup>5</sup>, Olivier Chabre<sup>6</sup>, Filippo Ceccato<sup>7</sup>, Andrea Daniele<sup>7</sup>, Mario Detomas<sup>8</sup>, Guido Di Dalmazi<sup>9</sup>, Atanaska Elenkova<sup>10</sup>, James Findling<sup>11</sup>, Ashley Grossman<sup>12</sup>, Celso E. Gomez-Sanchez<sup>13</sup>, Anthony P. Heaney<sup>14</sup>, Jürgen Honegger<sup>15</sup>, Niki Karavitaki<sup>16, 17, 18</sup>, Andre Lacroix<sup>19</sup>, Edward R. Laws<sup>20</sup>, Marco Losa<sup>21</sup>, Masanori Murakami<sup>1, 22</sup>, John D. Newell-Price<sup>23</sup>, Francesca Pecori Giraldi<sup>24</sup>, Luis G. Pérez-Rivas<sup>1</sup>, Rosario Pivonello<sup>25</sup>, William E. Rainey<sup>26</sup>, Silviu Sbiera<sup>8</sup>, Jochen Schopohl<sup>1</sup>, Constantine A. Stratakis<sup>27</sup>, Marily Theodoropoulou<sup>1</sup>, Elisabeth F.C. van Rossum<sup>28</sup>, Elena Valassi<sup>29</sup>, Sabina Zacharieva<sup>10</sup>, German Rubinstein<sup>1\*</sup>, Katrin Ritzel<sup>1\*</sup>.

\*equal contribution, §corresponding author

<sup>1</sup> Medizinische Klinik und Poliklinik IV, Klinikum der Ludwig-Maximilians-Universität München, Munich, Germany

<sup>2</sup> Université de Paris, Institut Cochin, INSERM, CNRS, F-75014 PARIS, France; Department of Endocrinology, Center for Rare Adrenal Diseases, AP-HP, Hôpital Cochin, F-75014, Paris, France

<sup>3</sup> Division of Endocrinology, Mayo Clinic, Rochester, MN 55905 USA

<sup>4</sup> Aix-Marseille Université, Institut National de la Santé et de la Recherche Médicale (INSERM), U1251, Marseille Medical Genetics (MMG), Institut MarMaRa and Endocrinology Department, Conception Hospital, Assistance Publique-Hôpitaux de Marseille (APHM), Marseille, France

<sup>5</sup> Neurochirurgische Klinik, Universitätsklinikum Erlangen, Germany

<sup>6</sup> Endocrinologie, Pavillon des Ecrins, CHU Grenoble-Alpes, CS 102017, 38043 Grenoble Cedex 9, France

<sup>7</sup> Endocrinology Unit, Dep of Medicine, DIMED, University-Hospital of Padova, Italy

<sup>8</sup> Division of Endocrinology and Diabetology, Department of Internal Medicine, University Hospital Würzburg, Würzburg, Germany

<sup>9</sup> Endocrinology and Diabetes Prevention and Care Unit, Department of Medical and Surgical Sciences, University of Bologna, S. Orsola Policlinic, 40138 Bologna, Italy

<sup>10</sup> Department of Endocrinology, Medical University Sofia, Sofia 1431, Bulgaria

<sup>11</sup> Division of Endocrinology and Molecular Medicine, Medical College of Wisconsin, Menomonee Falls, Wisconsin 53051, USA

<sup>12</sup> Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Centre for Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, UK

<sup>13</sup> Endocrine Service, G.V. Montgomery VA Medical Center and Department of Pharmacology and Toxicology and Medicine, University of Mississippi Medical Center, Jackson, MS, USA

<sup>14</sup> Division of Endocrinology, Medical Director, Pituitary & Neuroendocrine Tumor Program, UCLA School of Medicine, Los Angeles, CA 90024, USA

<sup>15</sup> Department of Neurosurgery, University of Tübingen, 72076 Tübingen, Germany

<sup>16</sup> Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham

- <sup>17</sup> Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners
- <sup>18</sup> Department of Endocrinology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
- <sup>19</sup> Division of Endocrinology, Department of Medicine, Centre hospitalier de l'Université de Montréal (CHUM), 900 Saint Denis, Montréal, Québec, H2X 0A9, Canada
- <sup>20</sup> Pituitary/Neuroendocrine Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
- <sup>21</sup> Department of Neurosurgery, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, 20132 Milan, Italy
- <sup>22</sup> Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
- <sup>23</sup> Dept of Oncology and Metabolism, The Medical School University of Sheffield Beech Hill Road, Sheffield S10 2RX, UK
- <sup>24</sup> Department of Clinical Sciences & Community Health, University of Milan; Neuroendocrinology Research Laboratory, Istituto Auxologico Italiano IRCCS, 20122 Milan, Italy
- <sup>25</sup> Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Università Federico II di Napoli, Naples, Italy
- <sup>26</sup> Departments of Molecular & Integrative Physiology and Medicine, University of Michigan, MSRBII, Ann Arbor, Michigan 48109, USA
- <sup>27</sup> Section on Genetics & Endocrinology Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) National Institute of Health (NIH), NIH Clinical Research Center, Bethesda, MD20892-1862, USA
- <sup>28</sup> Department of Internal Medicine, division of Endocrinology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
- <sup>29</sup> IIB-Sant Pau and Department of Endocrinology/Medicine, Hospital Sant Pau, UAB, and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER, Unidad 747), ISCIII, Barcelona, Spain

# **Title:**

**Corticotroph Tumor Progression after Bilateral Adrenalectomy (Nelson's syndrome): Systematic Review and Expert Consensus Recommendations.**

# **Correspondence:**

Prof. Dr. Martin Reincke  
Chairman, Department of Medicine IV  
Klinikum der Ludwig-Maximilians-Universität München  
Ziemssenstraße 1  
80336 München

106 Germany  
107 Email: martin.reincke@med.uni-muenchen.de  
108  
109 **Abstract: 186 words**

110 **Text: 6338 words**

111 **Tables: 0**

112 **Figures: 0**

113 **Online-only supplement: 4 tables**

114  
115 **Running title:** Consensus on diagnosis and treatment of corticotroph tumor  
116 progression  
117

118 **Key words:** Cushing's syndrome, cortisol, adrenocorticotrophic hormone,  
119 pituitary corticotroph adenoma, tumor growth, Nelson's tumor, radiation,  
120 transsphenoidal surgery, hypopituitarism  
121

122 **Abbreviations:**  
123 ACTH: Adrenocorticotrophic hormone  
124 BADX: bilateral adrenalectomy  
125 Cushing's disease: CD  
126 Cushing's syndrome: CS  
127 Glucocorticoid: GC  
128 MRI: magnetic resonance imaging  
129 Nelson's syndrome: NS  
130 Computed tomography: CT  
131 Magnetic resonance imaging: MRI  
132 Transsphenoidal surgery: TSS  
133 Conventional radiotherapy: CRT  
134 Stereotactic radiosurgery: SRS  
135

## Summary

BACKGROUND: Corticotroph tumor progression (CTP) leading to Nelson's syndrome (NS) is a severe and difficult-to-treat complication subsequent to bilateral adrenalectomy (BADX) for Cushing's disease. Its characteristics are not well described, and consensus recommendations for diagnosis and treatment are missing.

METHODS: A systematic literature search was performed focusing on clinical studies and case series ( $\geq 5$  patients). Definition, cumulative incidence, treatment and long-term outcomes of CTP/NS after BADX were analyzed using descriptive statistics. The results were presented and discussed at an interdisciplinary consensus workshop attended by international pituitary experts in Munich on October 28th, 2018.

RESULTS: Data covered definition and cumulative incidence (34 studies, 1275 patients), surgical outcome (12 studies, 187 patients), outcome of radiation therapy (21 studies, 273 patients), and medical therapy (15 studies, 72 patients).

CONCLUSIONS: We endorse the definition of CTP-BADX/NS as radiological progression or new detection of a pituitary tumor on thin-section MRI. We recommend surveillance by MRI after 3 months and every 12 months for the first 3 years after BADX. Subsequently, we suggest clinical evaluation every 12 months and MRI at increasing intervals every 2-4 years (depending on ACTH and clinical parameters). We recommend pituitary surgery as first-line therapy in patients with CTP-BADX/NS. Surgery should be performed before extrasellar expansion of the tumor to obtain complete and long-term remission. Conventional radiotherapy or stereotactic radiosurgery should be utilized as second-line treatment for remnant tumor tissue showing extrasellar extension

## Introduction

Cushing's disease (CD) is caused by a pituitary corticotroph adenoma producing sustained levels of adrenocorticotrophic hormone (ACTH), leading to excessive glucocorticoid secretion. The treatment of choice is transsphenoidal surgery (TSS) with selective removal of the adenoma tissue. Rates for persistence of CD or recurrence after initial remission were reported with a great variability depending on the ratio of micro-/macroadenoma, the experience of the surgeons and the definition for persistence and recurrence (1, 2). Based on meta-analyses the rates for persistence and recurrence after initial TSS ranged from 22% to 24% (persistence) (3-5) and 10-12% (recurrence), (4) respectively. Studies with a longer follow-up showed higher recurrence rates. Although the highest risk for recurrent disease is observed in the first five years (6), it can occur as late as several decades after surgery and lifelong surveillance for recurrence is essential. Second-line treatments in persistent and recurrent CD include repeat transsphenoidal surgery, fractionated pituitary radiation and radiosurgery, medical therapy targeting ACTH and cortisol excess, and bilateral adrenalectomy (BADX). BADX is highly effective but leads to permanent adrenal insufficiency requiring life-long steroid replacement therapy with the risk of life-threatening adrenal crisis. Therefore, BADX is generally considered the *ultima ratio* in CD treatment used when all other treatment options have failed. The use of BADX is highly variable between centers.

One of the possible complications occurring after BADX is the subsequent growth of the corticotroph tumor. Although the exact mechanism behind corticotroph tumor progression remains to be elucidated, it is believed that disinhibition of

the corticotroph tumor might be caused by reduced glucocorticoid feedback on tumor cells.

The surveillance, diagnosis and treatment of corticotroph tumors that progress (CTP), possibly leading to Nelson's syndrome (NS) is not standardized. To our knowledge there has never been a consensus on diagnosis and treatment. Therefore, we performed a systematic review of the literature on the definition of CTP after BADX leading to NS, its cumulative incidence, treatment and outcome of CTP. The results were presented and discussed at an interdisciplinary workshop attended by international pituitary experts in Munich on October 28th, 2018.

## **Methods of Literature Search and Consensus**

*Objective:* The objective of the current analysis was to develop an expert consensus for the management of patients with CTP after BADX leading to NS.

*Methods:* We performed a systematic literature search on MEDLINE using the search terms "Nelson's syndrome" or "Nelson syndrome" or "bilateral adrenalectomy" and "Cushing's disease". We searched for systematic reviews, clinical studies and case series ( $\geq 5$  patients). The search was limited to human studies and English language. We identified 635 publications, of which 80 met the inclusion criteria and were deemed to be relevant. The studies covered cumulative incidence (34 studies, 1275 patients undergoing BADX and 328 diagnosed with NS), surgical outcome (12 studies, 187 patients), outcome of radiation therapy (21 studies, 273 patients), and outcome of medical therapy (15 studies, 72 patients).

*Evidence:* We analyzed definition, key features, cumulative incidence, treatment and long-term outcomes of CTP/NS after BADX using descriptive statistics. The majority of the available data were of low quality (observational studies, unsystematic clinical experience, no randomized trials) and key outcome parameters could often not be defined due to the heterogeneity of the studies. For this reason, evidence was not formally graded. Analogue to the *Grading of Recommendations, Assessment, Development, and Evaluation Group* criteria (GRADE), we used “recommend” for strong recommendations and “suggest” for weak recommendations (7).

*Consensus Process:* We achieved consensus by collecting the best available evidence and conducting one group meeting on October 28, 2018 and exchanged multiple e-mail communications.

## **History, Terminology and Key Features**

In 1958 Don H. Nelson published the first description of a progressive ACTH-producing pituitary tumor following BADX; a case of deep pigmentation after BADX had already been recognized by Dr. Allan W. Spence at London’s St Bartholomew’s Hospital in 1957 (8). The syndrome, initially coined “post adrenalectomy syndrome”, was characterized by hyperpigmentation, elevated ACTH and an expanding sellar mass (9). One year later in 1959, Robert M. Salassa reported the first series of 5 patients with a progressive corticotroph tumor after bilateral adrenalectomy (10). Over time, the terminology “Nelson’s syndrome” was more widely used than “Nelson-Salassa syndrome” as indicated by the number of references in the scientific domain (Pubmed search: 598 hits vs 5 hits, April 2020).



In early studies, NS was often defined by the appearance of the clinical manifestations such as hyperpigmentation or a visual field defect. With advances in neuroimaging and the availability of computed tomography (CT) and later magnetic resonance imaging (MRI), clinical and laboratory indicators became less important for the diagnosis of NS. In 2007, the term “corticotroph tumor progression (CTP)” was proposed by Guillaume Assie and colleagues to amend or replace “Nelson’s syndrome”(11). This alternative terminology shifts the focus to the key feature of NS: An expanding pituitary corticotroph tumor as the primary clinical problem occurring subsequent to removal of both adrenal glands (BADX). However, NS is well established as medical eponym, and a change in medical terminology is difficult to achieve (12). Therefore, we suggest keeping NS as a supplement to CTP.

**Consensus Recommendation 1:** We suggest amending the terminology from “Nelson’s syndrome” (NS) to “Corticotroph Tumor Progression after bilateral adrenalectomy/Nelson’s syndrome” (CTP-BADX/NS, no grading).

## **Definition and Diagnosis of CTP-BADX /NS**

### *Corticotroph tumor progression in pituitary imaging*

In early publications, skull radiographs were used for diagnosing sellar masses (13-25). The assumption of pituitary tumor progression was based on findings of sellar enlargement, and distortion or thinning of the dorsum sellae. Also, clinical signs of tumor infiltration such as loss of vision were used for diagnosis. Since the 1980s pituitary tumors have been diagnosed with tomographic techniques (CT and later MRI, (11, 26-42)). Although CT allowed more accurate description

and earlier identification of pituitary tumor progression, diagnostic criteria were still heterogeneous. Some studies defined CTP-BADX/NS by the presence of a pituitary tumor on a post-adrenalectomy scan, while other studies requested progression or new occurrence. There were also inconsistencies in the interpretation of tumor size as a diagnostic marker. In the majority of studies, the presence of a microadenoma was sufficient to diagnose CTP-BADX/NS, while some publications required macroadenomas ( $\geq 10$  mm) or the need for clinical intervention (29, 31, 35, 39). From 2007 onwards, the definition of CTP-BADX/NS became more consistent, requiring significant tumor progression on neuroimaging (11, 38, 41, 42). Serial MRI with assessment of diameter, volume and potential parasellar extension has become the gold standard for the detection and evaluation of pituitary masses.

Precise volumetric measurement of pituitary tumors is often hampered by their irregular morphology, particularly after surgical resection, and standardized methods for imaging interpretation remain to be validated.

*Summary:* Radiological evidence of progression or a new occurrence of a pituitary tumor after BADX on MRI have become the basis for the diagnosis of CTP-BADX/NS in current clinical practice.

### *Hyperpigmentation*

Hyperpigmentation of the skin and mucous membranes after bilateral adrenalectomy is a common clinical feature caused by binding of ACTH and other POMC splicing products to the melanocortin-1 receptor (MC1R). Objective evaluation and quantification of this criterion is difficult because an individual's skin color is influenced by many factors, such as ethnicity or sun exposure. The

presence of MC1R genetic variants might also affect the degree of skin darkening, as previously reported for primary adrenal insufficiency (43). However, hyperpigmentation has served as a diagnostic criterion in several studies and has been documented in many publications. In earlier studies, before tomographic imaging was widely available, hyperpigmentation after BADX was more prevalent than expanding pituitary tumors (13-24, 26, 28, 30, 32, 35, 36). Interestingly, a recent study showed that a considerable number of patients with tumor progression on MRI had no obvious hyperpigmentation, indicating that tumor progression on MRI imaging might precede hyperpigmentation in some cases (42).

Although hyperpigmentation seems a less reliable diagnostic criterion than MRI documented tumor progression, it has clinical significance as a potential indicator of ACTH increase after BADX. In addition, hyperpigmentation can impact negatively on quality of life, especially at a younger age. The phenotypic changes associated with skin darkening are relevant for self-image and social interactions.

*Summary:* The new development or intensification of hyperpigmentation is an indicator of potential CTP and should lead to further diagnostic steps. A possible psychosocial impact on the affected patients, especially in children and adolescents, should also be carefully monitored in clinical practice.

#### *ACTH elevation*

ACTH as a tumor marker for CTP-BADX/NS has been measured and evaluated in most studies. Systematic comparisons between reports are difficult and limited by the use of different analytical methods (RIA vs. automated immunoassays),

309 different units (pmol/l vs. pg/ml) and different blood sampling protocols (e. g. in  
310 the morning before or in the morning following hydrocortisone substitution).  
311 The latter aspect needs special consideration since it has been shown that ACTH  
312 concentrations are profoundly influenced by the interval to the last  
313 glucocorticoid replacement dose (GC) (44). Another factor is that aggressive  
314 pituitary tumors after BADX might secrete high molecular weight ACTH, which  
315 cannot be detected by routine ACTH assays, resembling some 'silent'  
316 corticotroph adenomas (45). In general, ACTH measurement is challenging with  
317 complex preanalytical requirements. As a consequence, there is some  
318 controversy about the reliability of automated immunoassays (46, 47). Thus,  
319 caution is required not only in the interpretation of available research data but  
320 also in the use of plasma ACTH cut-offs as the basis for clinical decision making.  
321 Since spontaneous fluctuation of plasma ACTH can occur, monitoring of the  
322 ACTH level over time might be valuable to detect a progressive rise.

323 Most studies analyzed in the context of the present work showed increasing  
324 ACTH levels in patients following BADX. Similar to hyperpigmentation, ACTH  
325 elevation was more prevalent than radiologically-documented pituitary tumor  
326 progression, especially in earlier studies with less sophisticated imaging  
327 techniques (26, 28, 39). In direct comparison, average ACTH values were higher  
328 in patients with CTP-BADX/NS compared to patients without CTP-BADX/NS  
329 (956 vs 276 pg/ml (211 vs 61 pmol/l) (11, 34, 40, 48). The threshold of ACTH  
330 that could discriminate between patients with and without CTP-BADX/NS in  
331 different studies ranged from 200 to 700 pg/ml, with a mean of 396 pg/ml (44 to  
332 154 pmol/l, mean 87 pmol/l) (11, 21, 23, 28, 32, 34, 36, 38). *Summary: A*

consistent ACTH threshold indicating CTP-BADX/NS, as well as the timing of sampling remains to be established.

### *Conclusions*

In earlier descriptions, CTP-BADX/NS was defined by the typical triad (hyperpigmentation, elevated ACTH, and progressive pituitary adenoma). While the expanding pituitary tumor is the primary clinical problem, hyperpigmentation and elevated plasma ACTH are concomitant features. Available data suggest that hyperpigmentation and elevated ACTH are neither specific nor sensitive enough to be classified as primary diagnostic criteria for CTP-BADX/NS. Nonetheless, hyperpigmentation and ACTH excess are important clinical and biochemical evidence after BADX for CD, and possible indicators for CTP-BADX/NS. Longitudinal changes indicating an increase in ACTH seem to be more indicative for CTP-BADX/NS than an individual ACTH value after BADX. To standardize, sampling for ACTH measurement is recommended at 08:00 a.m. prior to the morning dose of GC (49).

**Consensus Recommendation 2:** As a primary criterion for the definition and diagnosis of CTP-BADX/NS, we recommend radiological evidence of corticotroph tumor progression or the new detection of a radiologically visible pituitary tumor after BADX. We further suggest hyperpigmentation and a progressive rise in plasma ACTH after BADX (assessed by immunoassay, at 08:00 h prior to the morning dose of GC) as non-mandatory secondary criteria of CTP-BADX/NS.

### **Cumulative incidence** of CTP-BADX/NS

*Cumulative incidence* of Nelson's syndrome in adults

Studies were excluded if the definition of CTP-BADX/NS was not given in the publication. The remaining 34 studies were analyzed on the basis of imaging modality (radiography versus tomography).

In the pre-tomography area, CTP-BADX/NS was mainly diagnosed by skull radiography. From 1971 until 1985, 10 publications investigated the cumulative incidence of CTP-BADX/NS in adults diagnosed with Cushing's disease who underwent BADX (13-15, 17, 19-24). CTP-BADX/NS occurred in 20% (0% - 46%) of the patients.

In studies published from 1990 onwards, CT and MRI have been mainly used for pituitary imaging. The mean cumulative incidence of CTP-BADX/NS in these studies was 29%, ranging from 8% to 53%. The large variability was due to the fact that the diagnostic criteria for CTP-BAD/NS were still heterogeneous (11, 26-42, 48). As an example, the lowest cumulative incidence of CTP-BADX/NS (8%) was observed in a study where CTP-BADX/NS was defined by the need for intervention for a pituitary tumor (39). A more consistent definition was introduced from 2007 onwards, with CTP-BADX/NS mainly defined by the new occurrence or significant corticotroph tumor progression on CT or MRI scans. The mean prevalence of CTP-BADX/NS in these studies was 43% (28-53%) (11, 38, 41, 42).

#### *Predictive factors*

Some publications were able to establish factors associated with an increased risk of developing CTP-BADX/NS (Table 2). High ACTH plasma concentrations in

the first year after BADX seemed to be predictive of CTP-BADX/NS (11, 21, 28, 34, 48). Patients with an obvious adenoma (33, 34) or larger tumor size before BADX (6mm vs. 1mm (42)) had an increased cumulative incidence of CTP-BADX/NS after BADX. Additionally, young age at BADX was positively associated with the appearance of CTP-BADX/NS. Patients younger than 35 years at BADX seem to have a particularly increased risk (22, 29, 37, 42). Cushing's disease has a female preponderance and more female than male patients undergo BADX. In 11 studies, specification of gender allowed calculation of the gender-related risk of CTP-BADX/NS (15-17, 21, 22, 29, 34, 36, 38, 42, 48). The majority of BADX patients were female (394 of 500). The mean proportion of female patients who developed CTP-BADX/NS was equivalent to the proportion of female patients in the group that was not diagnosed with CTP-BADX/NS (77.7 % vs. 78.4 %). While CD has higher preponderance in females, the cumulative incidence of CTP-BADX/NS is not sexually discordant. The effect of pregnancy on CTP-BADX/NS has been investigated in 11 women who became pregnant at a median time interval of 3.5 years after BADX by serial pituitary MRI before, during and after pregnancy. Interestingly, pregnancy did not accelerate corticotroph tumor progression (50).

The effect of radio therapy before BADX and prophylactic radio therapy on the risk of CTP-BADX has not been clarified yet and will be discussed later.

Patients with aggressive adenomas, not controlled by surgery and radiation, have a higher probability to undergo BADX for persistent or recurrent disease. These resistant adenomas might either be particularly sensitive to the loss of feedback inhibition after BADX or exhibit a distinct intrinsic aggressiveness. So

408 far, histopathological examination of pituitary tumors from transsphenoidal  
409 surgery *prior* to BADX could not identify a subtype that predicts the development  
410 of CTP-BADX/NS. Staining patterns as well as mitotic rates and Ki-67  
411 immunopositive nuclei from previous TSS were not different between patients  
412 developing CTP-BADX/NS and patients without CTP-BADX/NS (11, 42).

413 However, CTP-BADX/NS histology showed low p27 labeling indices and higher  
414 proliferation rates than corticotroph pituitary tumors from patients not  
415 undergoing BADX (51-53). Therefore, the role of histopathology and new  
416 molecular markers for the development of CTP-BADX/NS remains to be  
417 established by further research (54). Recently, somatic driver mutations in the  
418 ubiquitin specific protease 8 (*USP8*) gene have been implicated in the  
419 pathogenesis of Cushing's disease (55). These mutations appear to have a similar  
420 prevalence in CTP-BADX/NS, excluding the possibility that they drive the  
421 corticotroph tumor progression that leads to CTP-BADX/NS (56). Overall,  
422 progressing corticotroph tumors seem to be a heterogeneous group in terms of  
423 molecular characteristics and clinical behavior. and molecular pathways  
424 involved in growth regulation need to be further elucidated.

#### 426 *Cumulative incidence of Nelson's syndrome in childhood*

427 Three publications investigated the cumulative incidence of CTP-BADX/NS in  
428 childhood, all dating back to the pre-tomography era. The mean cumulative  
429 incidence of CTP-BADX/NS was considerably higher compared to results in adult  
430 patients (45%, 25-67%) (16, 18, 25). The lack of more recent data is most likely  
431 due to the rare occurrence of CD in childhood, and the restrictive use of BADX  
432 after evolution of transsphenoidal microsurgery (57).



433

434 *Time interval between BADX and diagnosis of CTP-BADX/NS*

435 The mean time interval between BADX and diagnosis of CTP-BADX/NS was 5.3  
436 years (9-11, 13-22, 56). However, the occurrence of CTP-BADX/NS has been  
437 reported from as little as 2 months up to 27 years after BADX (18, 38). In more  
438 recent studies, using CT or MRI imaging and more consistent criteria for CTP-  
439 BADX/NS, the time between BADX and CTP-BADX/NS was 2.5 years (0.2-8) (11,  
440 38, 41, 42). A previous study reported a median growth rate of 3 mm/year (0.5-  
441 21 mm) <sup>38</sup>: From these data, surveillance by tomographic imaging every 12  
442 months for the first 3 years seems reasonable.

443

444 *Conclusions*

445 The large variability in the **cumulative incidence** of CTP-BADX/NS and in the  
446 time of development after BADX may be mainly due to the lack of consistent  
447 diagnostic criteria. This emphasizes the need for a clear and standardized  
448 definition. CT and especially MRI imaging have a higher sensitivity than clinical  
449 and radiographic signs for the diagnosis of CTP-BADX/NS. The high CTP-  
450 BADX/NS **cumulative incidence** of around 40% in more recent publications  
451 probably reflects the true incidence of corticotroph tumor progression detected  
452 at an early stage. Since MRI allows diagnosis of tumor progression in the  
453 subclinical state, a diagnosis of CTP-BADX/NS does not necessarily need  
454 treatment but requires close follow-up

455

456 **Consensus Recommendation 3.1:** We recommend close surveillance in  
457 patients with any of the following conditions: 1. high plasma ACTH after BADX or

an increasing ACTH level; 2. visible corticotroph tumor prior to BADX; 3. patients younger than 35 years of age. The role of histopathological and molecular markers for the prediction of CTP-BADX/NS remains to be evaluated.

**Consensus Recommendation 3.2:** We recommend surveillance by MRI imaging (1-2 mm slice thickness) after 3 months and every 12 months for the first 3 years after BADX. CT should be only suggested as a method of second choice in patients with contraindications for MRI. We suggest clinical surveillance every 12 months and MRI imaging at increasing intervals every 2-4 years (depending on ACTH and clinical parameter) afterwards. In high-risk patients, closer surveillance might be required.

## **Outcome of pituitary surgery in CTP-BADX/NS**

### *Surgical series of patients with CTP-BADX/NS*

Successful surgical treatment of CTP-BADX/NS remains a great challenge. Because of the rarity of the syndrome, only 12 relevant clinical studies on outcome of neurosurgery have been reported since 1976 (187 patients).

### *Total hypophysectomy versus selective adenomectomy*

Most experts agree that neurosurgical resection of the pituitary tumor should be the first-line therapy in patients with CTP-BADX/NS. In the early years, total hypophysectomy was considered the preferred technique because of the potentially aggressive behavior of these tumors, a tendency to recurrence, and disappointing results of selective adenomectomy (58, 59). For example, in 1980 a study reported tumor control in 4 of 19 tumors by selective adenomectomy,

whereas 4 patients died as direct consequence of the tumor (59). Nevertheless, with advances in microsurgery, the outcomes of pituitary surgery have improved, leading to the recommendation to use selective adenomectomy as the preferred technique (60).

#### *Transsphenoidal versus transcranial approach*

The transsphenoidal approach is a relatively effective and safe procedure, and it is the preferred technique when feasible (37, 60-65). However, the outcomes of neurosurgery in CTP-BADX/NS are worse in comparison to those achieved in other types of pituitary tumors. Kasperlik-Zaluska and coworkers divided CTP-BADX/NS into three stages: stage I, pituitary microadenoma without any signs of invasion; stage II, pituitary macroadenoma without any invasion; stage III pituitary macroadenoma with extrasellar/parasellar invasion (37). In their series of 30 patients undergoing surgery, the transsphenoidal approach appeared to be the method of choice for stages I and II. They recommended a transcranial intervention, sometimes combined with radiotherapy, in patients with tumors having a large extrasellar invasion. In these cases, combined therapy may be the only way to attain partial remission, which was defined by the authors as a distinct improvement in the clinical course of NS, with reduced size of the pituitary tumor and decreased - but still exceeding the upper limit of normal - plasma ACTH levels. Similarly, Zielinski *et al*, recommend the transsphenoidal approach in the pre-invasive phase and the transcranial approach in invasive tumors (65). Our consensus panel emphasized transsphenoidal surgery as the preferred technique in the majority of the cases,

depending mostly on tumor localisation and growth direction, similar to the approach in other subtypes of pituitary tumors.

The interval between BADX and neurosurgery ranged from 7 months to 18 years, indicating the unpredictable behavior of these tumors (59, 60). Significant progression of the corticotroph tumor can occur quickly, leading to an extrasellar extension (62). In large tumors pituitary apoplexy can occur, leading to neurological complications and even death (37, 60). A significant proportion of CTP showed aggressive growth behaviour (13-21%) (37, 59). Cases of anaplastic pituitary tumors have been reported (37, 66).

#### *Remission rates of surgery*

The most relevant studies reporting on the outcome of pituitary surgery in patients with CTP-BADX/NS are summarized in Table 3. Remission rates after surgery ranged between 17% and 80%: Outcome was mainly influenced by tumor volume and the degree of extrasellar extension. However, different criteria of remission have been used over the years. All authors agree that a more favorable prognosis with fewer complications after neurosurgery occurs in microadenomas and intrasellar macroadenomas, whereas large tumors with cavernous sinus invasion have a low chance of complete tumor excision (62). Intrasellar tumors have been reported to be in remission after neurosurgery in 70-80% of the cases, leading also to a more pronounced reduction of plasma ACTH levels (60, 66, 67). The best surgical outcome in those patients treated at an early stage was documented in a large cohort of 30 patients with CTP-BADX/NS(37). Wilson and coworkers reported that none of the 10 patients with

macroadenomas had normalized plasma ACTH levels after neurosurgery (59). In Zielinski's report, all cases that did not achieve remission after surgery were grade IV tumors (according to the Knosp scale) with infiltration of the cavernous sinus (65, 68). The extent of parasellar growth, as measured by the Knosp scale, was established as the main factor influencing the effectiveness of surgical treatment. Accordingly, remission was documented only in patients with small tumors and limited intrasellar extension. All these data support early surgery, preferably before supra- or parasellar extension occurs.

Considering that tumors in patients with CTP-BADX/NS in historic series were mainly macroadenomas, visual field alterations secondary to optic chiasm compression occurred in 10%-51% of cases (58-63, 65-67). Neurosurgery can achieve improvement in visual defects through decompression of the optic chiasm (58, 61, 63, 65). Cranial nerve palsies such as cranial nerve III paresis, are also reported pre-operatively in this population with a frequency of 23%(61). Its complete or partial resolution after neurosurgery is documented (58, 61).

#### *Long-term follow-up after surgery*

A limited number of studies have reported long-term follow-up after neurosurgery in CTP-BADX/NS (Table 3). Xing and coworkers reported a mean follow-up of 3.6 years after neurosurgery in 23 patients with CTP-BADX/NS, with recurrence in 13% (63). Wislawski *et al.* documented the follow-up of 10 patients, ranging from 6 months to 10 years, and observed recurrences in 2 patients (20%), within 1 and 1.5 years respectively (66). In the series of Kelly *et al.*, long-term follow-up at a median of 17 years demonstrated normal

pigmentation, plasma ACTH levels less than 200 pg/ml (44 pmol/l) and no visible pituitary tumor in 6 of 13 patients with CTP-BADX/NS (61). In a small cohort of 6 patients with intrasellar CTP-BADX/NS, only one had a recurrent ACTH elevation after 10 years follow-up, without evidence of tumor regrowth (60).

Recently, a large retrospective study assessed the outcome of patients with CTP-BADX/NS followed for a median of 13 years (69). Of 68 patients with CTP-BADX/NS, 28 underwent pituitary surgery (n=10 surgery only; n=18 surgery plus radiotherapy), 22 radiotherapy alone, 2 were treated with pasireotide and 16 were observed without treatment. The 10-year tumor progression-free survival was higher in patients treated with pituitary surgery, either alone or in combination with radiotherapy, attaining a figure of ~80% (69).

#### *Side effects of surgery*

Pituitary surgery in CTP-BADX/NS is associated more frequently with side effects than primary TSS, since patients are more often subjected to repeated interventions. Still, cerebrospinal fluid leak (CSF) and meningitis have been rarely reported as complications (61, 65). Hypopituitarism or the onset of new pituitary deficits is reported in 5%-30% of cases (58, 60, 62, 64, 65). Exceptionally, Kelly *et al.* described hypopituitarism after surgery in a higher percentage (69%) (61). However, a total hypophysectomy was performed in all 13 patients. Permanent diabetes insipidus has been reported in 18-38% of cases (61, 62, 65). Mortality has been described as direct consequence of tumor progression, pituitary apoplexy or metastasis rather than a surgical complication

(37, 59, 62, 65, 69). Death shortly after pituitary surgery has been reported in few patients (37, 69).

#### *Conclusions*

The limitations of this analysis are the variable criteria used to define remission of CTP-BADX/NS and the lack of detailed information regarding imaging, biochemical values and other therapies used before and/or after neurosurgery in some studies. On the other hand, neurosurgical techniques have improved considerably over the last decades through the evolution of transsphenoidal approaches and modern microinstrumentation. The published data have demonstrated that transsphenoidal surgery is the first choice of treatment for CTP-BADX/NS and can be performed safely in the majority of patients.

#### **Consensus Recommendation 4.1**

We recommend pituitary surgery as first-line therapy in patients with CTP-BADX/NS. Surgery should be performed before extrasellar expansion of the tumor occurs in order to obtain complete and long-term remission.

#### **Consensus Recommendation 4.2**

We recommend selective removal of the pituitary adenoma by a transsphenoidal approach in micro- and macroadenomas, when technically feasible.

Transcranial surgery is to be discussed exclusively for supra-diaphragmatic locations, when extended transsphenoidal approach is not achievable or not

605 perceived as the optimal benefit/risk ratio (low evidence, weak  
606 recommendation).

607



## **Effect of prophylactic pituitary radiotherapy to prevent CTP-BADX/NS**

The available literature on this subject is sparse, many studies are based on data sources from previous decades and all data are retrospective.

Several studies have evaluated the effect of radiotherapy on the risk of developing CTP-BADX/NS. However, most studies have not clearly distinguished between prophylactic radiotherapy or therapeutic radiation of a corticotroph tumor prior to BADX. Additionally, the absence of a control group in several studies and the low number of patients receiving radiation limits interpretation.

Five of the studies (total n=149 patients with BADX of which 91 patients received radiation) reported a potential beneficial effect of radiation in reducing the cumulative incidence of CTP-BADX/NS (13, 21, 32, 38, 70). Conventional radiotherapy was used in 4 studies (30-50 Gy, fractionated). Two of these studies had control groups, showing a reduction in CTP-BADX/NS from 50% to 25% and 50% to 0 % in treated patients (32, 38). Radiosurgery was used in the most recent analysis with a remarkably low cumulative incidence of CTP-BADX/NS (5%) (70) after prophylactic gamma knife radiation.

In contrast to these publications, two studies (n=208 patients with BADX, of which 45 patients received radiation) could not confirm a risk reduction for CTP-BADX/NS by radiotherapy (15, 42). Another investigation found a high cumulative incidence of CTP-BADX/NS despite low dose pituitary radiation in a small group of patients (26). Together, the data are not sufficient for a general recommendation of prophylactic radiation, and the question whether radiotherapy can prevent CTP-BADX/NS remains unanswered. In particular, the

therapeutic effect of radiosurgery to prevent corticotroph tumor progression needs to be examined by further studies.

**Consensus Recommendation 5.1:** We suggest against the routine use of prophylactic pituitary radiation (fractionated or radiosurgery) to prevent corticotroph tumor progression. In cases of invasive macroadenomas with incomplete resection concomitant radiotherapy should be discussed by an interdisciplinary team before BADX.

#### **Radiation therapy of CTP-BADX/NS**

Radiation therapy can be used as a primary treatment option in pituitary adenomas, or secondary when surgical failure is evident. In general, the outcome of radiation therapy for CTP-BADX/NS is less favorable compared to other forms of pituitary adenomas. Radiation therapy is mainly divided into conventional radiotherapy (CRT) and stereotactic radiosurgery (SRS). Table 4 summarizes the outcomes of radiation therapy and its complications and side effects in patients with CTP-BADX/NS. None of these studies reported rates for peri and post procedural mortality.

#### *Conventional radiotherapy (CRT)*

CRT is based on an external photon source to radiate the targeted volume in 20-30 sessions and was used mainly in earlier years for the treatment of CTP-BADX/NS, although in total only 6 studies (1980-2019) with 58 patients have reported on its outcome (19, 62, 69, 71-73). Moreover, most of the studies focused on clinical and biochemical outcomes and lack data on radiological

outcomes and possible side effects of CRT. Comparison to more recent studies is difficult, as often radiation of the whole sellar region was performed and therefore radiotherapy-induced hypopituitarism was common. In addition, earlier studies used different ACTH assays, and imaging with MRI was not available. Howlett *et al.* studied 15 patients with CTP-BADX/NS treated with CRT (72). In 7 of them, CT scans were available demonstrating an empty sella after CRT in all (7/7, 100%). Kemink *et al.* reported tumor control in 5 of 6 patients (83%) (62). ACTH normalization was reported in 50%-60% of patients (62, 71). Two studies with 6 and 15 patients reported on new-onset hypopituitarism (5/6, 83%; and 2/15, 13%)(62, 72). As reported above, the largest study on the long-term outcome was recently published by Fountas *et al.*, reporting retrospectively on 22 patients treated from 1969-2018 in 13 UK pituitary centers by “radiotherapy” (19 with CRT, 2 with gamma knife surgery, 1 with cyber-knife surgery)(69). At 10-year follow up, 52% of these patients showed tumor progression-free survival compared to 81% of patients treated by pituitary surgery together with radiotherapy and 80% of subjects treated by surgery alone. However, no further information on radiotherapy (target volume, used dose) and imaging technique nor on side effects was given.

#### *Stereotactic radiosurgery*

Stereotactic radiosurgery (SRS) uses a very high dose of radiation (considered lethal to cells) applied from different angles (3D) to a precisely defined target volume. Its rationale is that by concentrating radiation on the biological target, more normal surrounding tissue can be preserved. It is usually applied in a single-session, but is sometimes split up into 5 sessions. For SRS different

technologies, sources of radiation and computer systems are used, but they all fulfill the above-mentioned characteristics: gamma-knife surgery (GKS) is the most frequently used technique, using gamma rays from a cobalt-60 source. Radiosurgery from linear accelerator systems (LINAC) uses accelerated electrons colliding with a target and therefore generating photons as the radiation source. Finally, proton-based SRS uses accelerated protons with favorable physical characteristics, but the technology is expensive and not widely available. As movement of the patient must be restricted, the patient's head gets fixed with either an invasive metal frame (in GKS) or a non-invasive mask (in LINAC).

Our systematic literature search identified 11 studies with outcome data on 179 patients (GKS: 7 studies with 150 patients (74-80); proton-based SRS: 2 studies with 15 patients (81, 82); LINAC: 2 studies with 14 patients (83, 84).

Different definitions of outcome were applied, most of them focused on biochemical and radiological remission, as defined by a decline or normalization of ACTH and stable or decreasing volume of the adenoma. The main therapeutic aim was tumor growth control. Information on pre- and post-treatment status was not reported in all studies, and interpretation of these results has to be handled with caution, because a high percentage of patients treated with radiosurgery was previously treated with multiple operations and CRT for CTP-BADX/NS. Therefore, the isolated effect of radiosurgery might be overestimated.

#### *Gamma knife surgery (GKS): efficacy*

The majority of the studies reported excellent tumor growth control rates, ranging from 82% to 100%. Since the studies had a mean follow-up of >50

months, and some even 85-144 months (77, 78), this indicates good long-term tumor control rates. In parallel, ACTH stabilization or an ACTH decrease was documented in 66 to 100% of the patients. The target volume was in the range of 1-2 ml. Post-radiation tumor volume shrinkage by 33% and 32% was documented in two studies (77, 79). In patients who achieved ACTH normalization, time from GKS to normalization was 115 and 162 months in two studies (77, 78). A shorter interval between transsphenoidal surgery and GKS was associated with a better endocrine remission (80).

#### *GKS: Side effects*

Adverse effects were reported in 6 of 7 studies. The most common adverse effect was new-onset hypopituitarism in 7%-40% of patients (22% in the largest series with 27 patients) (80). In some patients, the anti-tumor effect of GKS has led to improvement of pituitary function and tapering of replacement therapy (79). Visual field deficits and cranial nerves palsies (CNP; transitory and permanent) were reported in 19% and 14%, respectively (77, 78). It has to be noted, however, that many of the patients had received CRT before GKS, potentially increasing radiation-induced neuropathy. A single study reported that 10% of the patients had seizures (80). Additional radiation side effects, such as apoplexy and asymptomatic temporal lobe radiation necrosis, occurred in a small number of patients. (74, 77). One case of glioblastoma multiforme occurred 15 years after GKS in a brain area exposed to no more than 1 Gy which lead the authors to the conclusion that this event was probably not related to the procedure (79).

#### *Proton based SRS and SRS from LINAC*

Proton-based radiation has been suggested to have advantages over other forms of radiation as an even more precise and normal tissue sparing radiation might be possible. This so-called Bragg-peak effect allows protons to deposit almost all their energy in the targeted volume. So far, just two studies from 2008 and 2014 reported on 11 patients treated with proton-based SRS (81, 82). Stabilization of tumor growth was reported in both studies as 100%, ACTH normalization in 75% and 100%; 52% of patients developed new hypopituitarism (81).

Two studies including 14 patients reported outcome of LINAC radiosurgery (83, 84). Tumor control was achieved in 60% and 88% (83, 84) and new hypopituitarism developed in 20% (83).

#### *Other forms of radiation*

Early studies (1976, 1977) reported outcomes in 28 patients treated by radiation with heavy particles (910 MeV alpha), leading to improvement of hyperpigmentation and decline of ACTH (85, 86); one study from 1976 used the implantation of Yttrium-90 and Gold-198 seeds into the pituitary, by which also improvement and an ACTH decline could be achieved (87).

#### *Conclusions*

Radiation therapy is commonly used in CTP-BAD<sup>x</sup>/NS. In earlier years, CRT was widely used, with poorly documented outcome data. More recently, SRS with GKS has been used, leading to high tumor growth control rates of >90%. However, outcome data and side-effect rates of GKS have to be treated with caution, as most patients received CRT prior to GKS, the studies were retrospective, and essential data are often missing. Another major caveat is that

recent technical advances in conventional as well as stereotactic radiotherapy limit the transferability of earlier outcome data to modern radiotherapy. In summary, although of low quality, these data support the concept that radiation therapy can be safely used for CTP-BAD<sub>X</sub>/NS. In general, small tumor volumes are more suitable for SRS, whereas larger tumors may be more suitable for fractionated CRT.

**Recommendation 5.2:** We recommend radiation therapy for CTP-BAD<sub>X</sub>/NS in patients with tumors not safely accessible by surgery or when complete tumor resection is not possible by surgery. An interdisciplinary tumor board should govern the indication for treatment, the choice of treatment and radiation technique considering clinical, radiological and pathological characteristics.

## **Outcome of medical treatment in CTP-BADX/NS**

Medical therapy in CTP-BADX/NS has been reported in a limited number of studies. Early studies focused on plasma ACTH levels as the outcome indicator, since CTP could not be followed-up because of a lack of accurate imaging techniques (CT and MRI).

### *Medical therapy with a focus on plasma ACTH*

A few studies have investigated the effect of medical therapy on plasma ACTH as a surrogate marker of tumor growth. No effect was reported for either MSH release-inhibiting factor (MIF) or rosiglitazone (88-91). Reports on the efficacy of cyproheptadine, sodium valproate and dopamine agonists (bromocriptine and cabergoline) were heterogeneous. Whereas Krieger *et al.* reported an effect in 3 of 4 patients with CTP-BADX/NS treated with cyproheptadine 24 mg/day orally for 3-5 months, Cassar *et al.* observed no effect on ACTH levels in 3 patients receiving cyproheptadine 24 mg/per day orally for 6 weeks and 40 mg/day for 7 weeks (92, 93). Similarly, a single dose of 5 mg bromocriptine in 9 patients led to lowering of ACTH in one case, whereas a single dose of 2.5mg bromocriptine caused a significant decrease in plasma ACTH levels in 6 patients according to Mercado-Asis (94, 95). A few single case reports showed improvement of ACTH values and control of tumor growth with cabergoline, but larger studies are lacking (96). Sodium valproate 1200mg per day for 3 days resulted in lowered ACTH levels in 3 patients with CTP-BADX/NS (97). However, long-term therapy of 6 patients with sodium valproate 600mg per day for one year showed no significant effect on ACTH levels (98). In summary, these early studies do not



provide evidence for consistent pharmacological effect of any of the investigated medications.

#### *Medical therapy focusing on tumor growth*

The alkylating chemotherapeutic agent temozolomide has been used with limited efficacy. One patient with invasive CTP-BADX/NS received temozolomide 200 mg/m<sup>2</sup>/day orally for 5 days of a 28-day cycle, leading to tumor shrinkage, improvement of headaches and lowering of ACTH levels after 4 cycles of treatment (99). Another case report of a patient with an invasive corticotroph tumor receiving temozolomide 150mg/m<sup>2</sup>/day for 5 days every 28 days for 9 cycles resulted in marked clinical, biochemical, and radiological improvement. After stopping temozolomide tumor progression was observed after a 6-month period of remission, (100). Furthermore, there was a single case of stable disease (101) and a report of a lack of response in a patient despite absent MGMT expression (52, 102) receiving temozolomide for CTP-BADX/NS.

First-generation somatostatin analogues, acting on subtype-2 somatostatin receptors (SST2) were studied in a few patients: 100µg octreotide s.c. lowered ACTH levels and decreased tumor size in a patient with Nelson's syndrome (103); one patient received octreotide 300 µg/ day for a maximum of 2 years leading to lowered ACTH levels and tumor shrinkage (104); in another patient receiving the same regiment, visual field defects normalized (105). The somatostatin analogue pasireotide is a second-generation somatostatin receptor multi-ligand mainly acting on subtype 2 and 5 receptors (SST2, SST5). The

effects of pasireotide on corticotroph tumor growth are discussed controversially(106). A recently published study reported dose and time dependent reduction of tumor volume with pasireotide in patients with CD (107). Daniel *et al.* studied in an open-labeled multicenter longitudinal trial the effect of pasireotide in CTP-BADX/NS (49). Seven patients with subcutaneous treatment demonstrated a significant reduction in morning plasma ACTH of around 50%. This effect was maintained in 5 patients receiving long-acting pasireotide. An acute response to a test dose predicted outcome to long-term treatment in 4 of 5 patients. No significant change in tumor volumes was observed ( $1.4 \pm 0.9$  vs.  $1.3 \pm 1.0$ ,  $p = 0.86$ ). Four patients withdrew during the study. Hyperglycemia occurred in 6 patients. Besides lowering plasma ACTH levels, pasireotide had no major effects on tumor growth in patients with CTP-BADX/NS. Based on their study in 60 corticotroph adenomas, Hayashi *et al.* concluded that the presence of *USP8* mutations may predict favorable responses to pasireotide, whereas non-mutated aggressive tumors might respond better to temozolomide because of their significantly weak expression of MGMT.(108)

The clinical effectivity of medical treatment options preventing corticotroph tumor progression after BADX remains to be investigated in future studies.

**Recommendation 6:** There is no established medical therapy for CTP-BADX/NS. In aggressive corticotroph tumors resistant to other treatment options, we suggest the use of temozolomide on an individual basis.

## **Declaration of interest**

M Reincke has served on the advisory boards of Novartis and has received lecture fees and grants from Novartis, Ipsen, and Pfizer. I Bancos has served on the advisory boards of HRA Pharma and Corcept, and consulted for ClinCor. T Brue received consulting or speaker fees or grants from Novartis, Pfizer and Ipsen. He served as a board member or research investigator for Strongbridge, Pfizer, Ipsen and Recordati. O CHABRE received speaker fees from Novartis, has been an investigator in a clinical study financed by Novartis and is part of a board of HRA Pharma and Recordati. A Elenkova reports serving as the principal investigator/sub-investigator of clinical trials for Corcept Therapeutics and Novartis and receiving consulting honoraria from Novartis. Ashley Grossman has received lecture fees from Novartis, Ipsen, Pfizer and AAA. N Karavitaki has received educational grants from Novartis. A Lacroix received Clinical Trial Support from Novartis, GLWL Research Inc. and Corcept and served on advisory boards of Novartis, IPSEN and Pfizer. J Newell-Price has received research grants and consulting honoraria paid to the University of Sheffield from HRA Pharma, Novartis, Diurnal, and Ipsen. R Pivonello has been Principal Investigator of Research Studies for Novartis, HRA Pharma, Ipsen, Shire, Corcept Therapeutics, Cortendo AB; Co-investigator of Research Studies for Pfizer; received research grants from Novartis, Pfizer, Ipsen, HRA Pharma, Shire, IBSA; has been an occasional consultant for Novartis, Ipsen, Pfizer, Shire, HRA Pharma, Cortendo AB, Ferring and Italfarmaco; and has received fees and honoraria for presentations from Novartis and Shire. No conflict of interests that could be perceived as prejudicing the impartiality of this research reported. K Ritzel has

received lecture fee from Ipsen and served as investigator of clinical trials for Corcept. J Schopohl has received lecture fees from Novartis, Ipsen, and Pfizer. All the other authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

#### **Funding information**

The workshop was supported by unrestricted grants of the Deutsche Forschungsgemeinschaft (10.000 €; DFG, German Research Foundation, project number 314061271-TRR 205 “The adrenal gland: Central relay in health and disease”) of the Klinikum der Ludwig-Maximilians-Universität, and of the Carl Friedrich von Siemens Foundation, Munich. These funding sources had no role in the design of this study and did not have any role during its execution, analyses, interpretation of the data, or decision to submit results.

#### **Author’s contribution**

Martin Reincke: literature search, study design, data collection, analysis and interpretation (systematic review), writing\*. Adriana Albani: literature search, study design, data collection, analysis and interpretation (systematic review), writing\*. Guillaume Assie: data interpretation, writing. Irina Bancos: data interpretation, writing. Thierry Brue: data interpretation, writing. Michael Buchfelder: data interpretation, writing. Olivier Chabre: data interpretation, writing. Filippo Ceccato: data interpretation, writing. Andrea Daniele: data interpretation, writing. Mario Detomas: data interpretation, writing. Guido Di Dalmazi: data interpretation, writing. Atanaska Elenkova: data interpretation, writing. James Findling: data interpretation, writing. Ashley Grossman: data

890 interpretation, writing. Celso E. Gomez-Sanchez: data interpretation, writing.  
891 Anthony P. Heaney: data interpretation, writing. Jürgen Honegger: data  
892 interpretation, writing. Niki Karavitaki: data interpretation, writing. Andre  
893 Lacroix: data interpretation, writing. Edward R. Laws: data interpretation,  
894 writing. Marco Losa: data interpretation, writing. Masanori Murakami: data  
895 interpretation, writing. John D. Newell-Price: data interpretation, writing.  
896 Francesca Pecori Giraldi: data interpretation, writing. Luis G. Pérez - Rivas: data  
897 interpretation, writing. Rosario Pivonello: data interpretation, writing. William E.  
898 Rainey: data interpretation, writing. Silviu Sbiera: data interpretation, writing.  
899 Jochen Schopohl: data interpretation, writing. Constantine A. Stratakis: data  
900 interpretation, writing. Marily. Theodoropoulou: data interpretation, writing.  
901 Elisabeth F.C. van Rossum: data interpretation, writing. Elena Valassi: data  
902 interpretation, writing. Sabina Zacharieva: data. interpretation, writing. German  
903 Rubinstein: literature search, study design, data collection, analysis and  
904 interpretation (systematic review), writing\*. Katrin Ritzel: literature search,  
905 study design, data collection, analysis and interpretation (systematic review),  
906 writing\*  
907 \*= equal contribution

## References

1. Rubinstein G, Osswald A, Zopp S, Ritzel K, Theodoropoulou M, Beuschlein F, Reincke M. Therapeutic options after surgical failure in Cushing's disease: A critical review. *Best Practice & Research: Clinical Endocrinology & Metabolism*. 2019;**33**(2):101270.
2. Albani A, Theodoropoulou M. Persistent Cushing's Disease after Transsphenoidal Surgery: Challenges and Solutions. *Experimental and Clinical Endocrinology and Diabetes*. 2020.
3. Petersenn S, Beckers A, Ferone D, van der Lely A, Bollerslev J, Boscaro M, Brue T, Bruzzi P, Casanueva FF, Chanson P, et al. Therapy of endocrine disease: outcomes in patients with Cushing's disease undergoing transsphenoidal surgery: systematic review assessing criteria used to define remission and recurrence. *European Journal of Endocrinology of the European Federation of Endocrine Societies*. 2015;**172**(6):R227-39.
4. Dabrh AMA, Ospina NMS, Nofal AA, Farah WH, Barrionuevo P, Sarigianni M, Mohabbat AB, Benkhadra K, Leon BGC, Gionfriddo MR, et al. PREDICTORS OF BIOCHEMICAL REMISSION AND RECURRENCE AFTER SURGICAL AND RADIATION TREATMENTS OF CUSHING DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. *Endocrine Practice*. 2016;**22**(4):466-75.
5. Alexandraki KI, Kaltsas GA, Isidori AM, Storr HL, Afshar F, Sabin I, Akker SA, Chew SL, Drake WM, Monson JP, et al. Long-term remission and recurrence rates in Cushing's disease: predictive factors in a single-centre study. *European Journal of Endocrinology of the European Federation of Endocrine Societies*. 2013;**168**(4):639-48.
6. Braun LT, Rubinstein G, Zopp S, Vogel F, Schmid-Tannwald C, Escudero MP, Honegger J, Ladurner R, Reincke M. Recurrence after pituitary surgery in adult Cushing's disease: a systematic review on diagnosis and treatment. *Endocrine*. 2020;**70**(2):218-31.
7. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ, Group GW. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;**336**(7650):924-6.
8. Fraser R. Discussion on Cushing's syndrome. *Proc Roy Soc Med*. 1957;**50**:161-4.
9. Nelson DH, Meakin JW, Dealy JB, Jr., Matson DD, Emerson K, Jr., Thorn GW. ACTH-producing tumor of the pituitary gland. *N Engl J Med*. 1958;**259**(4):161-4.
10. Salassa RM, Kearns TP, Kernohan JW, Sprague RG, Maccarty CS. Pituitary tumors in patients with Cushing's syndrome. *J Clin Endocrinol Metab*. 1959;**19**:1523-39.
11. Assie G, Bahurel H, Coste J, Silvera S, Kujas M, Dugue MA, Karray F, Dousset B, Bertherat J, Legmann P, et al. Corticotroph tumor progression after adrenalectomy in Cushing's Disease: A reappraisal of Nelson's Syndrome. *J Clin Endocrinol Metab*. 2007;**92**(1):172-9.
12. Mora B, Bosch X. Medical eponyms: time for a name change. *Archives of Internal Medicine*. 2010;**170**(16):1499-500.
13. Orth DN, Liddle GW. Results of treatment in 108 patients with Cushing's syndrome. *N Engl J Med*. 1971;**285**(5):243-7.

- 955 14. Glenn F, Horwith M, Peterson RE, Mannix H, Jr. Total adrenalectomy for  
956 Cushing's disease. *Ann Surg.* 1972;**175**(6):948-55.
- 957 15. Moore TJ, Dluhy RG, Williams GH, Cain JP. Nelson's syndrome: frequency,  
958 prognosis, and effect of prior pituitary irradiation. *Ann Intern Med.*  
959 1976;**85**(6):731-4.
- 960 16. Hopwood NJ, Kenny FM. Incidence of Nelson's syndrome after  
961 adrenalectomy for Cushing's disease in children: results of a nationwide survey.  
962 *American Journal of Diseases of Children.* 1977;**131**(12):1353-6.
- 963 17. Cohen KL, Noth RH, Pechinski T. Incidence of pituitary tumors following  
964 adrenalectomy. A long-term follow-up study of patients treated for Cushing's  
965 disease. *Arch Intern Med.* 1978;**138**(4):575-9.
- 966 18. McArthur RG, Hayles AB, Salassa RM. Childhood Cushing disease: results  
967 of bilateral adrenalectomy. *J Pediatr.* 1979;**95**(2):214-9.
- 968 19. Sheeler LR, Grenfell RF, Jr., Schumacher OP, Kumar MS. Nelson's  
969 syndrome; a new look. *Cleve Clin Q.* 1980;**47**(4):299-304.
- 970 20. Tomita A, Suzuki S, Hara I, Oiso Y, Mizuno S, Yogo H, Kuwayama A,  
971 Kageyama N. Follow-up study on treatment in 27 patients with Cushing's  
972 disease: adrenalectomy, transsphenoidal adenomectomy and medical treatment.  
973 *Endocrinol Jpn.* 1981;**28**(2):197-205.
- 974 21. Barnett AH, Livesey JH, Friday K, Donald RA, Espiner EA. Comparison of  
975 preoperative and postoperative ACTH concentrations after bilateral  
976 adrenalectomy in Cushing's disease. *Clin Endocrinol (Oxf).* 1983;**18**(3):301-5.
- 977 22. Kasperlik-Zaluska AA, Nielubowicz J, Wislawski J, Hartwig W, Zaluska J,  
978 Jeske W, Migdalska B. Nelson's syndrome: incidence and prognosis. *Clin*  
979 *Endocrinol (Oxf).* 1983;**19**(6):693-8.
- 980 23. Kelly WF, MacFarlane IA, Longson D, Davies D, Sutcliffe H. Cushing's  
981 disease treated by total adrenalectomy: long-term observations of 43 patients. *Q*  
982 *J Med.* 1983;**52**(206):224-31.
- 983 24. Manolas KJ, Farmer HM, Wilson HK, Kennedy AL, Joplin GF, Montgomery  
984 DA, Kennedy TL, Welbourn RB. The pituitary before and after adrenalectomy for  
985 Cushing's syndrome. *World J Surg.* 1984;**8**(3):374-87.
- 986 25. Thomas CG, Jr., Smith AT, Benson M, Griffith J. Nelson's syndrome after  
987 Cushing's disease in childhood: a continuing problem. *Surgery.*  
988 1984;**96**(6):1067-77.
- 989 26. Littlely MD, Shalet SM, Beardwell CG, Ahmed SR, Sutton ML. Long-term  
990 follow-up of low-dose external pituitary irradiation for Cushing's disease. *Clin*  
991 *Endocrinol (Oxf).* 1990;**33**(4):445-55.
- 992 27. Grabner P, Hauer-Jensen M, Jervell J, Flatmark A. Long-term results of  
993 treatment of Cushing's disease by adrenalectomy. *Eur J Surg.* 1991;**157**(8):461-4.
- 994 28. McCance DR, Russell CF, Kennedy TL, Hadden DR, Kennedy L, Atkinson  
995 AB. Bilateral adrenalectomy: low mortality and morbidity in Cushing's disease.  
996 *Clin Endocrinol (Oxf).* 1993;**39**(3):315-21.
- 997 29. Kemink L, Pieters G, Hermus A, Smals A, Kloppenborg P. Patient's age is a  
998 simple predictive factor for the development of Nelson's syndrome after total  
999 adrenalectomy for Cushing's disease. *Journal of Clinical Endocrinology and*  
1000 *Metabolism.* 1994;**79**(3):887-9.
- 1001 30. Misra D, Kapur MM, Gupta DK. Incidence of Nelson's syndrome and  
1002 residual adrenocortical function in patients of Cushing's disease after bilateral  
1003 adrenalectomy. *J Assoc Physicians India.* 1994;**42**(4):304-5.

- 1004 31. O'Riordain DS, Farley DR, Young WF, Jr., Grant CS, van Heerden JA. Long-  
1005 term outcome of bilateral adrenalectomy in patients with Cushing's syndrome.  
1006 Surgery. 1994;**116**(6):1088-93; discussion 93-4.
- 1007 32. Jenkins PJ, Trainer PJ, Plowman PN, Shand WS, Grossman AB, Wass JA,  
1008 Besser GM. The long-term outcome after adrenalectomy and prophylactic  
1009 pituitary radiotherapy in adrenocorticotropin-dependent Cushing's syndrome. J  
1010 Clin Endocrinol Metab. 1995;**80**(1):165-71.
- 1011 33. Sonino N, Zielesny M, Fava GA, Fallo F, Boscaro M. Risk factors and long-  
1012 term outcome in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab.  
1013 1996;**81**(7):2647-52.
- 1014 34. Pereira MA, Halpern A, Salgado LR, Mendonca BB, Nery M, Liberman B,  
1015 Streeten DH, Wajchenberg BL. A study of patients with Nelson's syndrome.  
1016 Clinical Endocrinology. 1998;**49**(4):533-9.
- 1017 35. Imai T, Kikumori T, Funahashi H, Nakao A. Surgical management of  
1018 Cushing's syndrome. Biomed Pharmacother. 2000;**54 Suppl 1**:140s-5s.
- 1019 36. Nagesser SK, van Seters AP, Kievit J, Hermans J, Krans HM, van de Velde  
1020 CJ. Long-term results of total adrenalectomy for Cushing's disease. World J Surg.  
1021 2000;**24**(1):108-13.
- 1022 37. Kasperlik-Zaluska AA, Bonicki W, Jeske W, Janik J, Zgliczynski W,  
1023 Czernicki Z. Nelson's syndrome -- 46 years later: clinical experience with 37  
1024 patients. Zentralbl Neurochir. 2006;**67**(1):14-20.
- 1025 38. Gil-Cardenas A, Herrera MF, Diaz-Polanco A, Rios JM, Pantoja JP. Nelson's  
1026 syndrome after bilateral adrenalectomy for Cushing's disease. Surgery.  
1027 2007;**141**(2):147-51; discussion 51-2.
- 1028 39. Thompson SK, Hayman AV, Ludlam WH, Deveney CW, Loriaux DL,  
1029 Sheppard BC. Improved quality of life after bilateral laparoscopic adrenalectomy  
1030 for Cushing's disease: a 10-year experience. Ann Surg. 2007;**245**(5):790-4.
- 1031 40. Osswald A, Plomer E, Dimopoulou C, Milian M, Blaser R, Ritzel K, Mickisch  
1032 A, Knerr F, Stanojevic M, Hallfeldt K, et al. Favorable long-term outcomes of  
1033 bilateral adrenalectomy in Cushing's disease. Eur J Endocrinol.  
1034 2014;**171**(2):209-15.
- 1035 41. Prajapati OP, Verma AK, Mishra A, Agarwal G, Agarwal A, Mishra SK.  
1036 Bilateral adrenalectomy for Cushing's syndrome: Pros and cons. Indian J  
1037 Endocrinol Metab. 2015;**19**(6):834-40.
- 1038 42. Graffeo CS, Perry A, Carlstrom LP, Meyer FB, Atkinson JLD, Erickson D,  
1039 Nippoldt TB, Young WF, Jr., Pollock BE, Van Gompel JJ. Characterizing and  
1040 predicting the Nelson-Salassa syndrome. J Neurosurg. 2017;**127**(6):1277-87.
- 1041 43. Stratakis CA. "patients can have as many gene variants as they damn well  
1042 please": why contemporary genetics presents us daily with a version of Hickam's  
1043 dictum. Journal of Clinical Endocrinology and Metabolism. 2012;**97**(5):E802-4.
- 1044 44. Rousseau E, Joubert M, Trzepla G, Parienti JJ, Freret T, Vanthygem MC,  
1045 Desaillood R, Lefebvre H, Coquerel A, Reznik Y, et al. Usefulness of Time-Point  
1046 Serum Cortisol and ACTH Measurements for the Adjustment of Glucocorticoid  
1047 Replacement in Adrenal Insufficiency. PloS One. 2015;**10**(8):e0135975.
- 1048 45. Ben-Shlomo A, Cooper O. Silent corticotroph adenomas. Pituitary.  
1049 2018;**21**(2):183-93.
- 1050 46. Pecori Giralaldi F, Sacconi A, Cavagnini F, Endocrinology SGoTH-P-AAotIso.  
1051 Assessment of ACTH assay variability: a multicenter study. European Journal of



Endocrinology of the European Federation of Endocrine Societies. 2011;**164**(4):505-12.

47. Greene LW, Geer EB, Page-Wilson G, Findling JW, Raff H. Assay-Specific Spurious ACTH Results Lead to Misdiagnosis, Unnecessary Testing, and Surgical Misadventure-A Case Series. *J Endocr Soc.* 2019;**3**(4):763-72.

48. Cohen AC, Goldney DC, Danilowicz K, Manavela M, Rossi MA, Gomez RM, Cross GE, Bruno OD. Long-term outcome after bilateral adrenalectomy in Cushing's disease with focus on Nelson's syndrome. *Arch Endocrinol Metab.* 2019;**63**(5):470-7.

49. Daniel E, Debono M, Caunt S, Girio-Fragkoulakis C, Walters SJ, Akker SA, Grossman AB, Trainer PJ, Newell-Price J. A prospective longitudinal study of Pasireotide in Nelson's syndrome. *Pituitary.* 2018;**21**(3):247-55.

50. Jornayvaz FR, Assie G, Bienvenu-Perrard M, Coste J, Guignat L, Bertherat J, Silvera S, Bertagna X, Legmann P. Pregnancy does not accelerate corticotroph tumor progression in Nelson's syndrome. *Journal of Clinical Endocrinology and Metabolism.* 2011;**96**(4):E658-62.

51. Machado AL, Nomikos P, Kiesewetter F, Fahlbusch R, Buchfelder M. DNA-flow cytometry of 207 pituitary adenomas: ploidy, proliferation, and prognosis. *Journal of Endocrinological Investigation.* 2005;**28**(9):795-801.

52. Salehi F, Scheithauer BW, Moyes VJ, Drake WM, Syro LV, Manoranjan B, Sharma S, Horvath E, Kovacs K. Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome. *Endocrine Pathology.* 2010;**21**(4):227-9.

53. Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF, Jr., Meyer FB, Kuroki T, et al. Pathobiology of pituitary adenomas and carcinomas. *Neurosurgery.* 2006;**59**(2):341-53; discussion -53.

54. Grossman AB. The Molecular Pathology of Cushing Disease: Are We Nearly There? *J Endocr Soc.* 2017;**1**(2):144-8.

55. Reincke M, Sbiera S, Hayakawa A, Theodoropoulou M, Osswald A, Beuschlein F, Meitinger T, Mizuno-Yamasaki E, Kawaguchi K, Saeki Y, et al. Mutations in the deubiquitinase gene USP8 cause Cushing's disease. *Nature Genetics.* 2015;**47**(1):31-8.

56. Perez-Rivas LG, Theodoropoulou M, Puar TH, Fazel J, Stieg MR, Ferrau F, Assie G, Gadelha MR, Deutschbein T, Fragoso MC, et al. Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelson's tumor. *European Journal of Endocrinology of the European Federation of Endocrine Societies.* 2018;**178**(1):59-65.

57. Yordanova G, Martin L, Afshar F, Sabin I, Alusi G, Plowman NP, Riddoch F, Evanson J, Matson M, Grossman AB, et al. Long-term outcomes of children treated for Cushing's disease: a single center experience. *Pituitary.* 2016;**19**(6):612-24.

58. Ludecke D, Kautzky R, Saeger W, Schrader D. Selective removal of hypersecreting pituitary adenomas? An analysis of endocrine function, operative and microscopical findings in 101 cases. *Acta Neurochirurgica.* 1976;**35**(1-3):27-42.

59. Wilson CB, Tyrrell JB, Fitzgerald PA, Pitts LH. Cushing's disease and Nelson's syndrome. *Clinical Neurosurgery.* 1980;**27**:19-30.

- 1099 60. Ludecke DK, Breustedt HJ, Bramswig J, Kobberling J, Saeger W. Evaluation  
1100 of surgically treated Nelson's syndrome. *Acta Neurochirurgica*. 1982;**65**(1-2):3-  
1101 13.
- 1102 61. Kelly PA, Samandouras G, Grossman AB, Afshar F, Besser GM, Jenkins PJ.  
1103 Neurosurgical treatment of Nelson's syndrome. *Journal of Clinical Endocrinology*  
1104 *and Metabolism*. 2002;**87**(12):5465-9.
- 1105 62. Kemink SA, Grotenhuis JA, De Vries J, Pieters GF, Hermus AR, Smals AG.  
1106 Management of Nelson's syndrome: observations in fifteen patients. *Clinical*  
1107 *Endocrinology*. 2001;**54**(1):45-52.
- 1108 63. Xing B, Ren Z, Su C, Wang R, Yang Y, Hu Y. Microsurgical treatment of  
1109 Nelson's syndrome. *Chinese Medical Journal (Engl)*. 2002;**115**(8):1150-2.
- 1110 64. De Tommasi C, Vance ML, Okonkwo DO, Diallo A, Laws ER, Jr. Surgical  
1111 management of adrenocorticotrophic hormone-secreting macroadenomas:  
1112 outcome and challenges in patients with Cushing's disease or Nelson's syndrome.  
1113 *Journal of Neurosurgery*. 2005;**103**(5):825-30.
- 1114 65. Zielinski G, Witek P, Maksymowicz M. Outcomes in pituitary surgery in  
1115 Nelson's syndrome--therapeutic pitfalls. *Endokrynologia Polska*.  
1116 2015;**66**(6):504-13.
- 1117 66. Wislawski J, Kasperlik-Zaluska AA, Jeske W, Migdalska B, Janik J, Zaluska J,  
1118 Bonicki W. Results of neurosurgical treatment by a transsphenoidal approach in  
1119 10 patients with Nelson's syndrome. *Journal of Neurosurgery*. 1985;**62**(1):68-71.
- 1120 67. Fukushima T. Trans-sphenoidal microsurgical treatment of Nelson's  
1121 syndrome. *Neurosurgical Review*. 1985;**8**(3-4):185-94.
- 1122 68. Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of  
1123 the cavernous sinus space: a magnetic resonance imaging classification  
1124 compared with surgical findings. *Neurosurgery*. 1993;**33**(4):610-7; discussion 7-  
1125 8.
- 1126 69. Fountas A, Lim ES, Drake WM, Powlson AS, Gurnell M, Martin NM, Seejore  
1127 K, Murray RD, MacFarlane J, Ahluwalia R, et al. Outcomes of patients with  
1128 Nelson's syndrome after primary treatment: a multicenter study from 13 UK  
1129 Pituitary centers. *Journal of Clinical Endocrinology and Metabolism*. 2019.
- 1130 70. Mehta GU, Sheehan JP, Vance ML. Effect of stereotactic radiosurgery  
1131 before bilateral adrenalectomy for Cushing's disease on the incidence of Nelson's  
1132 syndrome. *J Neurosurg*. 2013;**119**(6):1493-7.
- 1133 71. Tran LM, Blount L, Horton D, Sadeghi A, Parker RG. Radiation therapy of  
1134 pituitary tumors: results in 95 cases. *American Journal of Clinical Oncology*.  
1135 1991;**14**(1):25-9.
- 1136 72. Howlett TA, Plowman PN, Wass JA, Rees LH, Jones AE, Besser GM.  
1137 Megavoltage pituitary irradiation in the management of Cushing's disease and  
1138 Nelson's syndrome: long-term follow-up. *Clinical Endocrinology*.  
1139 1989;**31**(3):309-23.
- 1140 73. Grigsby PW, Stokes S, Marks JE, Simpson JR. Prognostic factors and results  
1141 of radiotherapy alone in the management of pituitary adenomas. *International*  
1142 *Journal of Radiation Oncology, Biology, Physics*. 1988;**15**(5):1103-10.
- 1143 74. Pollock BE, Young WF, Jr. Stereotactic radiosurgery for patients with  
1144 ACTH-producing pituitary adenomas after prior adrenalectomy. *International*  
1145 *Journal of Radiation Oncology, Biology, Physics*. 2002;**54**(3):839-41.
- 1146 75. Mauermann WJ, Sheehan JP, Chernavvsky DR, Laws ER, Steiner L, Vance  
1147 ML. Gamma Knife surgery for adrenocorticotrophic hormone-producing pituitary

adenomas after bilateral adrenalectomy. *Journal of Neurosurgery*. 2007;**106**(6):988-93.

76. Jane JA, Jr., Vance ML, Woodburn CJ, Laws ER, Jr. Stereotactic radiosurgery for hypersecreting pituitary tumors: part of a multimodality approach. *Neurosurgical Focus*. 2003;**14**(5):e12.

77. Caruso JP, Patibandla MR, Xu Z, Vance ML, Sheehan JP. A Long-Term Study of the Treatment of Nelson's Syndrome With Gamma Knife Radiosurgery. *Neurosurgery*. 2018;**83**(3):430-6.

78. Marek J, Jezkova J, Hana V, Krsek M, Liscak R, Vladyka V, Pecen L. Gamma knife radiosurgery for Cushing's disease and Nelson's syndrome. *Pituitary*. 2015;**18**(3):376-84.

79. Vik-Mo EO, Oksnes M, Pedersen PH, Wentzel-Larsen T, Rodahl E, Thorsen F, Schreiner T, Aanderud S, Lund-Johansen M. Gamma knife stereotactic radiosurgery of Nelson syndrome. *European Journal of Endocrinology of the European Federation of Endocrine Societies*. 2009;**160**(2):143-8.

80. Cordeiro D, Xu Z, Li CE, Iorio-Morin C, Mathieu D, Sisterson ND, Kano H, Attuati L, Picozzi P, Sheehan KA, et al. Gamma Knife radiosurgery for the treatment of Nelson's syndrome: a multicenter, international study. *Journal of Neurosurgery*. 2019:1-6.

81. Petit JH, Biller BM, Yock TI, Swearingen B, Coen JJ, Chapman P, Ancukiewicz M, Bussiere M, Klibanski A, Loeffler JS. Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. *Journal of Clinical Endocrinology and Metabolism*. 2008;**93**(2):393-9.

82. Wattson DA, Tanguturi SK, Spiegel DY, Niemierko A, Biller BM, Nachtigall LB, Bussiere MR, Swearingen B, Chapman PH, Loeffler JS, et al. Outcomes of proton therapy for patients with functional pituitary adenomas. *International Journal of Radiation Oncology, Biology, Physics*. 2014;**90**(3):532-9.

83. Wilson PJ, Williams JR, Smee RI. Nelson's syndrome: single centre experience using the linear accelerator (LINAC) for stereotactic radiosurgery and fractionated stereotactic radiotherapy. *Journal of Clinical Neuroscience*. 2014;**21**(9):1520-4.

84. Voges J, Kocher M, Runge M, Poggenborg J, Lehrke R, Lenartz D, Maarouf M, Gouni-Berthold I, Krone W, Muller RP, et al. Linear accelerator radiosurgery for pituitary macroadenomas: a 7-year follow-up study. *Cancer*. 2006;**107**(6):1355-64.

85. Lawrence JH, Tobias CA, Linfoot JA, Born JL, Chong CY. Heavy-particle therapy in acromegaly and Cushing disease. *JAMA*. 1976;**235**(21):2307-10.

86. Linfoot JA, Nakagawa JS, Wiedemann E, Lyman J, Chong C, Garcia J, Lawrence JH. Heavy particle therapy: pituitary tumors. *Bulletin of the Los Angeles Neurological Societies*. 1977;**42**(3-4):175-89.

87. Cassar J, Doyle FH, Lewis PD, Mashiter K, Noorden S, Joplin GF. Treatment of Nelson's syndrome by pituitary implantation of yttrium-90 or gold-198. *British Medical Journal*. 1976;**2**(6030):269-72.

88. Donnadieu M, Laurent MF, Luton JP, Bricaire H, Girard F, Binoux M. Synthetic MIF has no effect on beta-MSH and ACTH hypersecretion in Nelson's syndrome. *Journal of Clinical Endocrinology and Metabolism*. 1976;**42**(6):1145-8.

- 1195 89. Mullan KR, Leslie H, McCance DR, Sheridan B, Atkinson AB. The PPAR-  
1196 gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with  
1197 Nelson's syndrome. *Clinical Endocrinology*. 2006;**64**(5):519-22.
- 1198 90. Munir A, Song F, Ince P, Walters SJ, Ross R, Newell-Price J. Ineffectiveness  
1199 of rosiglitazone therapy in Nelson's syndrome. *Journal of Clinical Endocrinology*  
1200 *and Metabolism*. 2007;**92**(5):1758-63.
- 1201 91. Kreutzer J, Jeske I, Hofmann B, Blumcke I, Fahlbusch R, Buchfelder M,  
1202 Buslei R. No effect of the PPAR-gamma agonist rosiglitazone on ACTH or cortisol  
1203 secretion in Nelson's syndrome and Cushing's disease in vitro and in vivo.  
1204 *Clinical Neuropathology*. 2009;**28**(6):430-9.
- 1205 92. Krieger DT, Luria M. Effectiveness of cyproheptadine in decreasing  
1206 plasma ACTH concentrations in Nelson's syndrome. *Journal of Clinical*  
1207 *Endocrinology and Metabolism*. 1976;**43**(5):1179-82.
- 1208 93. Cassar J, Mashiter K, Joplin GF, Rees LH, Gilkes JJ. Cyproheptadine in  
1209 Nelson's syndrome. *Lancet*. 1976;**2**(7982):426.
- 1210 94. O'Mullane N, Walker B, Jefferson J, Hipkin L, Diver M, Davis C. Lack of  
1211 effect of bromocriptine on ACTH levels in patients with bilateral adrenalectomy  
1212 for pituitary-dependent Cushing's syndrome. *Journal of Endocrinological*  
1213 *Investigation*. 1978;**1**(4):355-7.
- 1214 95. Mercado-Asis LB, Yanovski JA, Tracer HL, Chik CL, Cutler GB, Jr. Acute  
1215 effects of bromocriptine, cyproheptadine, and valproic acid on plasma  
1216 adrenocorticotropin secretion in Nelson's syndrome. *Journal of Clinical*  
1217 *Endocrinology and Metabolism*. 1997;**82**(2):514-7.
- 1218 96. Shraga-Slutsky I, Shimon I, Weinshtein R. Clinical and biochemical  
1219 stabilization of Nelson's syndrome with long-term low-dose cabergoline  
1220 treatment. *Pituitary*. 2006;**9**(2):151-4.
- 1221 97. Kasperlik-Zaluska AA, Zgliczynski W, Jeske W, Zdunowski P. ACTH  
1222 responses to somatostatin, valproic acid and dexamethasone in Nelson's  
1223 syndrome. *Neuro Endocrinology Letters*. 2005;**26**(6):709-12.
- 1224 98. Kelly W, Adams JE, Laing I, Longson D, Davies D. Long-term treatment of  
1225 Nelson's syndrome with sodium valproate. *Clinical Endocrinology*.  
1226 1988;**28**(2):195-204.
- 1227 99. Moyes VJ, Alusi G, Sabin HI, Evanson J, Berney DM, Kovacs K, Monson JP,  
1228 Plowman PN, Drake WM. Treatment of Nelson's syndrome with temozolomide.  
1229 *European Journal of Endocrinology of the European Federation of Endocrine*  
1230 *Societies*. 2009;**160**(1):115-9.
- 1231 100. Kurowska M, Nowakowski A, Zielinski G, Malicka J, Tarach JS,  
1232 Maksymowicz M, Denew P. Temozolomide-Induced Shrinkage of Invasive  
1233 Pituitary Adenoma in Patient with Nelson's Syndrome: A Case Report and  
1234 Review of the Literature. *Case Rep Endocrinol*. 2015;**2015**:623092.
- 1235 101. Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M, Cangi MG,  
1236 Talarico A, Mortini P, Reni M. Salvage therapy with temozolomide in patients  
1237 with aggressive or metastatic pituitary adenomas: experience in six cases.  
1238 *European Journal of Endocrinology of the European Federation of Endocrine*  
1239 *Societies*. 2010;**163**(6):843-51.
- 1240 102. Bruno OD, Juarez-Allen L, Christiansen SB, Manavela M, Danilowicz K,  
1241 Vigovich C, Gomez RM. Temozolomide Therapy for Aggressive Pituitary Tumors:  
1242 Results in a Small Series of Patients from Argentina. *International Journal of*  
1243 *Endocrinology*. 2015;**2015**:587893.

- 1244 103. Kelestimur F, Utas C, Ozbakir O, Selcuklu A, Kandemir O, Ozcan N. The  
1245 effects of octreotide in a patient with Nelson's syndrome. *Postgraduate Medical*  
1246 *Journal*. 1996;**72**(843):53-4.
- 1247 104. Petrini L, Gasperi M, Pilosu R, Marcello A, Martino E. Long-term treatment  
1248 of Nelson's syndrome by octreotide: a case report. *Journal of Endocrinological*  
1249 *Investigation*. 1994;**17**(2):135-9.
- 1250 105. Lamberts SW, Uitterlinden P, Klijn JM. The effect of the long-acting  
1251 somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome  
1252 and Cushing's disease. *Acta Endocrinologica*. 1989;**120**(6):760-6.
- 1253 106. Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V,  
1254 Trouillas J, Dekkers OM, European Society of E. European Society of  
1255 Endocrinology Clinical Practice Guidelines for the management of aggressive  
1256 pituitary tumours and carcinomas. *European Journal of Endocrinology of the*  
1257 *European Federation of Endocrine Societies*. 2018;**178**(1):G1-G24.
- 1258 107. Lacroix A, Gu F, Schopohl J, Kandra A, Pedroncelli AM, Jin L, Pivonello R.  
1259 Pasireotide treatment significantly reduces tumor volume in patients with  
1260 Cushing's disease: results from a Phase 3 study. *Pituitary*. 2020;**23**(3):203-11.
- 1261 108. Hayashi K, Inoshita N, Kawaguchi K, Ibrahim Ardisasmita A, Suzuki H,  
1262 Fukuhara N, Okada M, Nishioka H, Takeuchi Y, Komada M, et al. The USP8  
1263 mutational status may predict drug susceptibility in corticotroph adenomas of  
1264 Cushing's disease. *European Journal of Endocrinology of the European*  
1265 *Federation of Endocrine Societies*. 2016;**174**(2):213-26.

1268

First Author	year	Follow up (y)*	Age (y)*	n BADX (f/m)	n CTP-BADX (%)	Interval BADX CTP-BADX (y)
Orth	1971	8	NA	19	0 (0)	NA
Glenn	1972	10	NA	42	3 (7)	NA
Moore	1976	8	NA	120 (97/23)	9 (8)	7
Hopwood	1977	5	12	32 (16/16)	8 (25)	3
Cohen	1978	9	30	21 (19/2)	8 (38)	7
McArthur	1979	1-27	4-19	27 (10/17)	12 (44)	10
Sheeler	1980	NA	NA	17	6 (35)	NA
Tomita	1981	NA	NA	19	1 (5)	NA
Kelly	1983	10	NA	38	11 (29)	5
Barnett	1983	5	38	15 (13/2)	3 (20)	NA
Kasperlik-Zaluska	1983	12	42	50 (45/5)	14 (28)	5
Manolas	1984	11	40	65	14 (22)	NA
Thomas	1984	NA	8-17	6	4 (67)	8
Littley	1990	1-14	28	9 (9/0)	3 (33)	NA
Grabner	1991	13	NA	94	10 (11)	10
McCance	1993	5	46	26	9 (35)	NA
Misra	1994	2-10	36	18 (10/8)	2 (11)	NA
Kemink,	1994	10	16-55	48 (44/4)	8 (17)	7
O'Riordain	1994	5	NA	20	3 (15)	NA
Jenkins	1995	NA	39	38	11 (29)	1
Sonino	1996	9	NA	63	15 (24)	NA
Pereira	1998	8	32	30 (22/8)	14 (47)	5
Imai	2000	25	NA	16	4 (25)	NA
Nagesser	2000	19	40	44 (33/11)	10 (23)	NA
Kasperlik-Zaluska	2006	NA	NA	52	23 (43)	NA
Thompson	2007	4	42	36	3 (8)	NA
Gil-Cárdenas	2007	4	31	39 (32/7)	11(28)	1
Assie	2007	5	38	53 (45/8)	25 (47)	3
Smith	2009	5	45	40 (43/6)	13(33)	NA
Ding	2010	4	NA	34	6 (18)	NA
Oßwald	2014	11	NA	29	7 (24)	4
Prajapati	2015	3	NA	12	58 (42)	3
Graffeo	2017	16	NA	88	47 (53)	3
Cohen	2019	14	28	13 (9/4)	6 (46)	2

**Table 1:**

Summary of studies reporting on cumulative incidence of CTP-BADX/NS.

\*mean or range

1274

Author	n after BADX		Age at BADX		% female		ACTH after BADX (pg/ml)	
	CTP	no CTP	CTP	no CTP	CTP	no CTP	CTP	no CTP
Moore	9	111	30	35	88	75	NA	NA
Kelly	11	27	45	38	NA	NA	>240	60
Kemink,	8	40	26 ± 6 *	36 ± 11 *	100	90	NA	NA
Pereira	14	16	31 ± 8	32 ± 8	63	86	1726 ± 668*	268 ± 236*
Nagesser	10	34	33	40	90	70	NA	NA
Gil-Cardenas	11	39	28	31	64	89	NA	NA
Assie	25	28	no predictor <sup>§</sup>		no predictor <sup>§</sup>		Predictor <sup>§</sup>	
Graffeo	47	41	35 ± 2 *	49 ± 2 *	79	73	690 ± 177	NA
Cohen	6	7	29 ± 12	27 ± 7	67	71	476 (240-1500)*	81 (48-330)*

1275 \*statistically significant (p &lt; 0.05)

1276 § regression model

1277

1278 **Table 2:** Potential predictors of CTP-BADX/NS in studies directly comparing risk  
 1279 factors in patients with CD who developed CTP-BADX/NS vs. patients who did  
 1280 not after BADX.

1281

1282 **Separately attached**

1283

1284 **Table 3:**

1285 Summary of studies reporting on outcome of pituitary surgery in patients with  
1286 CTP-BADX/ NS.

1287

1288 **Table 4:**

1289 Summary of studies reporting the outcomes of radiation therapy in patients  
1290 with CTP-BADX/NS.

1291